Video

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

This study showed that it is feasible to think outside the box when considering patient recruitment. In this study, researchers used social media and the Internet to recruit patients. In total, Gitlitz says, 44% of patients came through these means.

Researchers greatly exceeded their statistical expectations, Gitlitz says. For patients with lung adenocarcinoma, researchers set a bar close to the Lung Cancer Mutation Consortium and wanted to demonstrate an increase in actionable mutations from 35% to 50%. In actuality, they found actionable mutations in 76% of patients.

<<<

View more from the 2015 World Conference on Lung Cancer

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute